Good stuff. Pfizer's multivalent meningococcal vaccine was approved by the FDA for individuals aged 10-25 years old. It targets serogroups A, C, W, Y, and B all in one vaccine.
We currently have two meningococcal vaccines broadly speaking targeting either B or A, C, W, and Y. Serogroup B causes most of meningococcal disease in children and young adults in the US. Serogroups C, W, and Y cause most of meningococcal disease in adults.
ACIP will meet Wednesday to determine its usage.